Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report report published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a research note on Thursday, November 14th. […]

Leave a Reply

Your email address will not be published.

Previous post Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by BTIG Research to Buy Rating
Next post BMO Capital Markets Lowers Ascot Resources (TSE:AOT) Price Target to C$0.75